[CLINICAL TRIALS robarts A GLOBAL RESEARCH ORGANIZATION

Robarts Translational Research Consortium

presents an inaugural symposium on

JAK-STAT Modulation in IBD – from Bench to Bedside

January 13, 2019

Taos, New Mexico USA

Event Sponsors

Theravance Biopharma
Medicines That Make a Difference®

progenity®

Mount Sinai SERVICES

Pfizer

[CONNECT] robartsclinicaltrials.com

Canada
100 Dundas Street
Suite 200
London, Ontario
Canada N6A 5B6

USA
4350 Executive Drive
Suite 210
San Diego, California
USA 92121

Europe
Pietersbergweg 17
Trinity Building C
1105 BM Amsterdam
The Netherlands

[CLINICAL TRIALS robarts A GLOBAL RESEARCH ORGANIZATION

Symposium on JAK-STAT Modulation in IBD – from Bench to Bedside

Agenda for January 13, 2019

at Sagebrush Inn & Suites, Taos, NM

7:45 AM **Registration**

8:15 AM **Welcome & Introductions**

Session 1: Clinical Efficacy & Safety

Co-chairs: Dr. William Sandborn & Dr. Bram Verstockt

8:45 AM *State of the art: mechanism of action of JAK-STAT inhibition*
Dr. Massimo Gadina – National Institutes of Health, USA

9:10 AM *Efficacy in inflammatory bowel diseases*
Dr. Severine Vermeire – KU Leuven, Belgium

9:35 AM *Safety of JAK-STAT inhibition*
Dr. Brian Feagan – Western University / Robarts Clinical Trials, Canada

10:00 AM Panel discussion
10:15 AM Break

Session 2: Clinical Pharmacology & Translational Medicine

Co-chairs: Dr. Stefania Vetrano & Dr. Manuel Braga Neto

10:30 AM *Drug interactions, metabolism and excretion*
Dr. Niels Vande Casteele – UC San Diego / Robarts Clinical Trials, USA

10:55 AM *Peripheral immune system vs. mucosal immunology*
Dr. Azucena Salas – IDIBAPS, Spain

11:20 AM *Predictors for response, treatment intensification, and/or discontinuation*
Dr. Eoin McKinney – University of Cambridge, UK

11:45 AM Panel discussion
Noon Lunch

[CLINICAL TRIALS robarts A GLOBAL RESEARCH ORGANIZATION

Session 3: Drug Design & Development

Co-chairs: Dr. Dermot McGovern & Dr. Isabella Dotti

1:00 PM *Improving efficacy and safety: Compound engineering vs. drug delivery*
Dr. Andrew Long – AbbVie, USA

1:25 PM *Combination therapy redefined*
Dr. Marjolijn Duijvestein – AMC, the Netherlands

1:50 PM *Overview of the pipeline and strategies for efficient drug development*
Dr. William Sandborn – UC San Diego, USA

2:15 PM Panel discussion
2:40 PM Break

Session 4: Breakout Session

Co-chairs: Dr. Severine Vermeire & Dr. Niels Vande Casteele

3:00 PM Working groups to identify areas of translational research that can guide treatment strategies and accelerate further drug development

4:00 PM Working group presentation & general discussion
5:00 PM Summary of proposed objectives
5:10 PM Adjourn

- Reception to Follow -